Search

Author/Creator Simeone, Ester

4. Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab. Issue 1 (16th July 2018)

Authors:
Capone, Mariaelena; Giannarelli, Diana; Mallardo, Domenico; Madonna, Gabriele; Festino, Lucia; Grimaldi, Antonio Maria; Vanella, Vito; Simeone, Ester; Paone, Miriam; Palmieri, Giuseppe; Cavalcanti, Ernesta; Caracò, Corrado; Ascierto, Paolo Antonio
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 6:Issue 1(2018)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Correlation between BRAF mutational status and clinical response to pembrolizumab in advanced melanoma patients. (4th November 2015)

Authors:
Simeone, Ester; Grimaldi, Antonio Maria; Festino, Lucia; Giannarelli, Diana; Palla, Marco; Caracò, Corrado; Curvietto, Marcello; Esposito, Assunta; Paone, Miriam; Rinaldi, Giovanni; Grimaldi, Maria Chiara; Mozzillo, Nicola; Ascierto, Paolo A
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 3(2015)Supplement 2
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Correlation between BRAF mutational status and clinical response to pembrolizumab in advanced melanoma patients. Issue 2 (December 2015)

Authors:
Simeone, Ester; Grimaldi, Antonio; Festino, Lucia; Giannarelli, Diana; Palla, Marco; Caracò, Corrado; Curvietto, Marcello; Esposito, Assunta; Paone, Miriam; Rinaldi, Giovanni; Grimaldi, Maria; Mozzillo, Nicola; Ascierto, Paolo
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 3:Issue 2(2015)
Page Start:
1
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Correlation between immune-related adverse events and response to pembrolizumab in advanced melanoma patients. (4th November 2015)

Authors:
Grimaldi, Antonio Maria; Simeone, Ester; Festino, Lucia; Giannarelli, Diana; Palla, Marco; Caracò, Corrado; Curvietto, Marcello; Esposito, Assunta; Grimaldi, Maria Chiara; Mozzillo, Nicola; Ascierto, Paolo A
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 3(2015)Supplement 2
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. Correlation between immune-related adverse events and response to pembrolizumab in advanced melanoma patients. Issue 2 (December 2015)

Authors:
Grimaldi, Antonio; Simeone, Ester; Festino, Lucia; Giannarelli, Diana; Palla, Marco; Caracò, Corrado; Curvietto, Marcello; Esposito, Assunta; Grimaldi, Maria; Mozzillo, Nicola; Ascierto, Paolo
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 3:Issue 2(2015)
Page Start:
1
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. Correlation between previous treatment with BRAF inhibitors and clinical response to pembrolizumab in patients with advanced melanoma. (4th March 2017)

Authors:
Simeone, Ester; Grimaldi, Antonio Maria; Festino, Lucia; Giannarelli, Diana; Vanella, Vito; Palla, Marco; Curvietto, Marcello; Esposito, Assunta; Palmieri, Giuseppe; Mozzillo, Nicola; Ascierto, Paolo Antonio
Journal:
Oncoimmunology
Issue:
Volume 6:Number 3(2017)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. CTLA-4 gene variant -1661A>G may predict the onset of endocrine adverse events in metastatic melanoma patients treated with ipilimumab. (July 2018)

Authors:
Queirolo, Paola; Dozin, Beatrice; Morabito, Anna; Banelli, Barbara; Carosio, Roberta; Fontana, Vincenzo; Ferrucci, Pier Francesco; Martinoli, Chiara; Cocorocchio, Emilia; Ascierto, Paolo A.; Madonna, Gabriele; Simeone, Ester; De Galitiis, Federica; Antonini Cappellini, Gian Carlo; Marchetti, Paol...
Journal:
European journal of cancer
Issue:
Volume 97(2018)
Page Start:
59
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗